Scientists and researchers of Queensland University of Technology and Oxford University are working in collaboration to begin clinical trials for corticosteroids, commonly used for asthma patients, on patients suffering from COVID-19. The novel coronavirus or SARS-CoV-2 has infected over 11.79 million people around the world and killed over 543,000 individuals to date. It has led to severe complications in some individuals with underlying causes. Researchers around the world are in search of drugs that could help reduce the severity of complications of COVID-19. The said clinical trial is being registered under the name of STOIC (STerOids in COVID-19). It has begun recruiting patients at the Churchill Hospital in Oxford, England. If successful, Budesonide inhaler therapy could be a low cost and readily available therapy for early COVID-19 patients. It would reduce their risk of getting severe respiratory complications, said Professor Nicolau.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here